* BioTransplant Inc., of Charlestown, Mass., said underwriters of itsrecent initial public offering exercised their full overallotment optionon 420,000 shares at $9.50 per share. The company is developinganti-rejection drugs and organ transplantation systems.
* Oxis International Inc., of Portland, Ore., raised $2 million througha private placement of two million shares of Series D preferred stock,together with warrants to purchase another 810,000 shares. Thecompany is developing drugs and diagnostics to combat diseasesassociated with free radicals and reactive oxygen species.
* The Liposome Co., of Princeton, N.J., received approval to marketAbelcet (amphotericin B lipid complex) in Portugal for severe,systemic fungal infections in refractory patients.
(c) 1997 American Health Consultants. All rights reserved.